Unknown

Dataset Information

0

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.


ABSTRACT: Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-positive expression (n = 136), LIPI (Lung Immune Prognostic Index) score of 0 (n = 116). In our cohort, lack of TTF1 expression, LIPI score >0, line of treatment >1, and liver metastases were associated with poorer PFS. TTF1 and PD-L1 status could be used to stratify survival and improve the AUC for prediction of prognosis in comparison with the PD-L1 gold standard. Using an external cohort of 154 patients, we confirmed the independent prognostic role of TTF1. TTF1 expression and PD-L1 can be used to stratify risk and predict PFS and OS in patients treated with ICI for NS-NSCLC.

SUBMITTER: Galland L 

PROVIDER: S-EPMC8331027 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

Galland Loïck L   Le Page Anne Laure AL   Lecuelle Julie J   Bibeau Frederic F   Oulkhouir Youssef Y   Derangère Valentin V   Truntzer Caroline C   Ghiringhelli François F  

Oncoimmunology 20210802 1


Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival und  ...[more]

Similar Datasets

| S-EPMC8611937 | biostudies-literature
| S-EPMC6171018 | biostudies-literature
| S-EPMC5173037 | biostudies-literature
| S-EPMC6333638 | biostudies-literature
| S-EPMC8533876 | biostudies-literature
| S-EPMC11465384 | biostudies-literature
| S-EPMC4546461 | biostudies-literature
| S-EPMC10147600 | biostudies-literature
| S-EPMC8090457 | biostudies-literature
| S-EPMC6792277 | biostudies-literature